BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Macnaughtan J, Jalan R. Clinical and Pathophysiological Consequences of Alterations in the Microbiome in Cirrhosis. American Journal of Gastroenterology 2015;110:1399-410. [DOI: 10.1038/ajg.2015.313] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Bhat M, Arendt BM, Bhat V, Renner EL, Humar A, Allard JP. Implication of the intestinal microbiome in complications of cirrhosis. World J Hepatol 2016; 8(27): 1128-1136 [PMID: 27721918 DOI: 10.4254/wjh.v8.i27.1128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
2 Watt KD. The evolving role of the microbiome in liver failure and liver transplantation. Liver Transpl 2016;22:58-61. [PMID: 27588961 DOI: 10.1002/lt.24623] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Iebba V, Guerrieri F, Di Gregorio V, Levrero M, Gagliardi A, Santangelo F, Sobolev AP, Circi S, Giannelli V, Mannina L, Schippa S, Merli M. Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. Sci Rep 2018;8:8210. [PMID: 29844325 DOI: 10.1038/s41598-018-26509-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
4 Huan H, Hu H, Chen XH, Gao WN, Li LL, Li J, Deng K, Liu C. Diversity of intestinal microflora in tibetan patients with liver cirrhosis based on high-throughput sequencing. Shijie Huaren Xiaohua Zazhi 2019; 27(18): 1142-1148 [DOI: 10.11569/wcjd.v27.i18.1142] [Reference Citation Analysis]
5 Oikonomou T, Papatheodoridis GV, Samarkos M, Goulis I, Cholongitas E. Clinical impact of microbiome in patients with decompensated cirrhosis. World J Gastroenterol 2018; 24(34): 3813-3820 [PMID: 30228776 DOI: 10.3748/wjg.v24.i34.3813] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
6 Chen YX, Lai LN, Zhang HY, Bi YH, Meng L, Li XJ, Tian XX, Wang LM, Fan YM, Zhao ZF, Han DW, Ji C. Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis. World J Gastroenterol 2016; 22(10): 2949-2959 [PMID: 26973391 DOI: 10.3748/wjg.v22.i10.2949] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
7 Strnad P, Tacke F, Koch A, Trautwein C. Liver - guardian, modifier and target of sepsis. Nat Rev Gastroenterol Hepatol. 2017;14:55-66. [PMID: 27924081 DOI: 10.1038/nrgastro.2016.168] [Cited by in Crossref: 168] [Cited by in F6Publishing: 155] [Article Influence: 28.0] [Reference Citation Analysis]
8 Giuffrè M, Campigotto M, Campisciano G, Comar M, Crocè LS. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature. Am J Physiol Gastrointest Liver Physiol 2020;318:G889-906. [PMID: 32146836 DOI: 10.1152/ajpgi.00161.2019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
9 . UEG Week 2020 Oral Presentations. United European Gastroenterol j 2020;8:8-142. [DOI: 10.1177/2050640620927344] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Woodhouse C, Singanayagam A, Patel VC. Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis. Clin Med (Lond) 2020;20:493-500. [PMID: 32934044 DOI: 10.7861/clinmed.2020-0676] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Heidrich B, Vital M, Plumeier I, Döscher N, Kahl S, Kirschner J, Ziegert S, Solbach P, Lenzen H, Potthoff A, Manns MP, Wedemeyer H, Pieper DH. Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls.Liver Int. 2018;38:50-58. [PMID: 28561276 DOI: 10.1111/liv.13485] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
12 Macnaughtan J, Figorilli F, García-López E, Lu H, Jones H, Sawhney R, Suzuki K, Fairclough S, Marsden J, Moratella A, Cox IJ, Thomas L, Davies N, Williams R, Mookerjee R, Wright G, Jalan R. A Double-Blind, Randomized Placebo-Controlled Trial of Probiotic Lactobacillus casei Shirota in Stable Cirrhotic Patients.Nutrients. 2020;12. [PMID: 32498372 DOI: 10.3390/nu12061651] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
13 Macnaughtan J, Mookerjee RP, van der Merwe S, Jalan R. Lipopolysaccharide-Induced Neutrophil Dysfunction Following Transjugular Intrahepatic Portosystemic Stent Shunt (TIPSS) Insertion is Associated with Organ Failure and Mortality. Sci Rep 2017;7:40157. [PMID: 28051160 DOI: 10.1038/srep40157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
14 Tilg H, Mathurin P. Altered intestinal microbiota as a major driving force in alcoholic steatohepatitis. Gut 2016;65:728-9. [DOI: 10.1136/gutjnl-2015-311014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sanduzzi Zamparelli M, Rocco A, Compare D, Nardone G. The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma. United European Gastroenterol J. 2017;5:944-953. [PMID: 29163959 DOI: 10.1177/2050640617705576] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
16 Kato K, Nagao M, Miyamoto K, Oka K, Takahashi M, Yamamoto M, Matsumura Y, Kaido T, Uemoto S, Ichiyama S. Longitudinal Analysis of the Intestinal Microbiota in Liver Transplantation. Transplant Direct. 2017;3:e144. [PMID: 28405600 DOI: 10.1097/txd.0000000000000661] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
17 Howell J, Pinato DJ, Ramaswami R, Bettinger D, Arizumi T, Ferrari C, Yen C, Gibbin A, Burlone ME, Guaschino G, Sellers L, Black J, Pirisi M, Kudo M, Thimme R, Park J, Sharma R. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. Aliment Pharmacol Ther 2017;45:1146-55. [DOI: 10.1111/apt.13977] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
18 Cheng D, Xie MZ. A review of a potential and promising probiotic candidate-Akkermansia muciniphila. J Appl Microbiol 2021;130:1813-22. [PMID: 33113228 DOI: 10.1111/jam.14911] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Wong YJ, Kalki RC, Lin KW, Kumar R, Tan J, Teo EK, Li JW, Ang TL. Short- and long-term predictors of spontaneous bacterial peritonitis in Singapore. Singapore Med J 2020;61:419-25. [PMID: 31363784 DOI: 10.11622/smedj.2019085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Grander C, Adolph TE, Wieser V, Lowe P, Wrzosek L, Gyongyosi B, Ward DV, Grabherr F, Gerner RR, Pfister A, Enrich B, Ciocan D, Macheiner S, Mayr L, Drach M, Moser P, Moschen AR, Perlemuter G, Szabo G, Cassard AM, Tilg H. Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut. 2018;67:891-901. [PMID: 28550049 DOI: 10.1136/gutjnl-2016-313432] [Cited by in Crossref: 192] [Cited by in F6Publishing: 185] [Article Influence: 38.4] [Reference Citation Analysis]
21 Kaliszewski E, Parker A. Severe Protein Calorie Malnutrition in the Context of Alcoholic Liver Cirrhosis: A Case Study Evaluation. Topics in Clinical Nutrition 2018;33:335-45. [DOI: 10.1097/tin.0000000000000157] [Reference Citation Analysis]
22 Adolph TE, Grander C, Moschen AR, Tilg H. Liver–Microbiome Axis in Health and Disease. Trends in Immunology 2018;39:712-23. [DOI: 10.1016/j.it.2018.05.002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 14.3] [Reference Citation Analysis]
23 Tripathi DM, Vilaseca M, Lafoz E, Garcia-Calderó H, Viegas Haute G, Fernández-Iglesias A, Rodrigues de Oliveira J, García-Pagán JC, Bosch J, Gracia-Sancho J. Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension. Gastroenterology 2018;155:1564-77. [PMID: 30055171 DOI: 10.1053/j.gastro.2018.07.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
24 Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut. 2016;65:2035-2044. [PMID: 27802157 DOI: 10.1136/gutjnl-2016-312729] [Cited by in Crossref: 202] [Cited by in F6Publishing: 186] [Article Influence: 33.7] [Reference Citation Analysis]
25 Coscia C, Saxton E, Dickinson S. Postoperative Care of a Liver Transplant Recipient Using a Classification System: Type A (Stable) Versus Type B (Unstable). Crit Care Nurs Q 2016;39:252-66. [PMID: 27254641 DOI: 10.1097/CNQ.0000000000000119] [Reference Citation Analysis]
26 Santiago A, Pozuelo M, Poca M, Gely C, Nieto JC, Torras X, Román E, Campos D, Sarrabayrouse G, Vidal S, Alvarado-Tapias E, Guarner F, Soriano G, Manichanh C, Guarner C. Alteration of the serum microbiome composition in cirrhotic patients with ascites. Sci Rep 2016;6:25001. [PMID: 27112233 DOI: 10.1038/srep25001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]